炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月19日，药明康德收涨2.08%，收盘价为92.47元，发生10笔大宗交易，合计成交量300万股，成交金 额2.64亿元。 第1笔成交价格为87.85元，成交78.96万股，成交金额6,936.74万元，溢价率为-5.00%，买方营业部为机 构专用，卖方营业部为华泰证券股份有限公司上海分公司。 第6笔成交价格为87.85元，成交19.95万股，成交金额1,752.63万元，溢价率为-5.00%，买方营业部为瑞 银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第7笔成交价格为87.85元，成交16.49万股，成交金额1,448.31万元，溢价率为-5.00%，买方营业部为瑞 银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第8笔成交价格为87.85元，成交6.23万股，成交金额547.49万元，溢价率为-5.00%，买方营业部为瑞银 证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第9笔成交价格为87.85元，成 ...

中国经济网北京12月19日讯 药明康德(603259.SH)昨日晚间发布关于股东权益变动触及1%刻度的提 示性公告。 2025年11月26日至2025年12月17日，药明康德加权均价为91.477元。经计算，上述股东减持金额合 计约26.99亿元。 (责任编辑：田云绯) 2025年12月17日，公司收到信息披露义务人发出的通知，获知其于2025年11月26日至2025年12月17 日通过集中竞价和大宗交易方式合计减持公司股份29,508,754股，占公告日公司总股本的0.989%。信息 披露义务人及与实际控制人签署投票委托书的股东合计持有公司股份数从535,711,396股减少至 506,202,642股，持股比例从17.95%减少至16.97%，权益变动触及1%刻度。 公司实际控制人为Ge Li（李革）、张朝晖、刘晓钟。信息披露义务人G&C IV Hong Kong Limited、G&C V Limited、G&C VI Limited、G&C VII Limited、嘉兴厚锦投资合伙企业（有限合伙）、 嘉兴厚毅投资合伙企业（有限合伙）、嘉兴厚毓投资合伙企业（有限合伙）、嘉兴厚咨投资合伙企业 （有限合伙） ...

药明康德股东权益变动公告要点解读 一、权益变动核心情况 •变动方向：控股股东及其一致行动人减持 •持股变化：从17.95%减少至16.97%，下降0.98个百分点 •减 持规模：2,950.88万股，占总股本0.989% •变动时间：2025年11月26日至12月17日 二、减持方式及数量 •集中竞价减持：2,983.67万股，占总股本1% •大宗交易减持：1,150万股，占总股本0.39% •减持主体： 包括G&C IV至VII Limited等4家境外公司及多家嘉兴、上海投资合伙企业 三、关键信息 •实际控制人：李革、张朝晖、刘晓钟 •合规性：本次减持符合此前披露的减持计划，未违反相关承诺 • 影响评估：不触发强制要约收购，不改变实际控制人地位 •后续安排：减持股东仍处于减持计划实施期 间，公司将继续监督执行情况 ...

每经AI快讯，药明康德（SH 603259，收盘价：90.59元）12月18日晚间发布公告称，2025年12月18日， 公司全资子公司WuXi Lux Holding与Jeito Capital S.A.S.签署Subion Agreement，约定由WuXi Lux Holding 认缴投资基金1000万欧元的A类份额，对应已募集投资基金份额的1.07%。同日，WuXi Lux Holding与 WuXi PharmaTech Healthcare Fund I L.P.签署Transfer Agreement，约定WuXi Lux Holding按照最近一期投 资人账户净资产价值及未出资认缴金额的总和受让WuXi Fund I持有的2000万欧元基金认缴份额。转让 协议与认购协议完成后，WuXiLuxHolding将合计持有投资基金3,000万欧元的A类份额，约占已募集投 资基金份额的3.22%。截至本公告日，WuXi LuxHolding尚未支付投资款，后续WuXiLuxHolding将以自 有资金根据认购协议及转让协议的约定履行转让款及后续投资款的支付义务。 2025年1至6月份，药明康德的营业收入构 ...

（编辑 姚尧） 证券日报网讯 12月17日晚间，普蕊斯发布公告称，普蕊斯（上海）医药科技开发股份有限公司（以下 简称"公司"）于2025年11月19日披露了《关于公司股东减持股份预披露公告》，公司股东淄博弘润盈科 创业投资合伙企业（有限合伙）（曾用名：平潭弘润盈科新材料创业投资合伙企业（有限合伙）、福州 弘润盈科新材料创业投资中心（有限合伙），以下简称"弘润盈科"）、股东石河子市睿新股权投资合伙 企业（有限合伙）（以下简称"石河子睿新"）和财务总监宋卫红计划自减持计划公告发布之日起15个交 易日后的3个月内以集中竞价交易方式分别减持本公司股份不超过6，500股（占本公司总股本比例 0.0082%）、73，100股（占本公司总股本比例0.0925%）、800股（占本公司总股本比例0.0010%）。近 日，公司收到股东弘润盈科、石河子睿新和财务总监宋卫红女士分别出具的《关于股份减持计划实施完 成的告知函》，截至本公告披露日，上述股东的减持计划已实施完成。 ...

证券日报网讯12月17日，博济医药（300404）在互动平台回答投资者提问时表示，目前公司在美国有成 熟的承接中美双报业务的子公司及团队；成立的美国临床子公司目前也已承接海外临床业务；国内组建 了海外业务部门用于承接国际多中心临床项目；通过引入有国际业务经验的人才，积极拓展国外临床业 务。 ...

香港联交所最新数据显示，12月11日，摩根大通增持药明康德（603259）(02359)87.2123万股，每股作 价106.3228港元，总金额约为9272.66万港元。增持后最新持股数目约为3141.66万股，持股比例为 6.15%。 ...

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has signed an agreement with Peking University Health Science Center to establish the "Peking University Medicine - Sunshine Nuohuo Innovative Drug Joint Laboratory," focusing on cutting-edge fields such as cell therapy and gene therapy to develop clinical candidate drugs [1][2]. Group 1: Overview of Cooperation - The collaboration aims to enhance independent innovation capabilities and national core competitiveness, promoting quality improvement in innovative research and development [2]. - The partnership does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1]. Group 2: Basic Information of Partners - Peking University Health Science Center is the first western medical school established by the Chinese government and is part of the "211 Project," with a strong foundation in teaching, research, and medical education [3]. - There are no existing relationships of dishonesty or conflicts of interest between the partners [4]. Group 3: Main Content of the Cooperation Agreement - The agreement outlines that Peking University will organize research efforts, while Sunshine Nuohuo will provide funding and address technical challenges [5][6]. - The laboratory will focus on developing world-class clinical candidate drugs, including innovative therapies in cell and gene treatment [7][10]. Group 4: Funding and Management - Sunshine Nuohuo will provide a total of RMB 20 million (approximately 2 million) for the laboratory's operation, with an initial funding of RMB 10 million (approximately 1 million) to be transferred within 30 working days of the agreement [9]. - The intellectual property rights from the research conducted in the laboratory will be jointly owned by both parties, typically shared equally [9]. Group 5: Impact on the Company - This collaboration is a strategic move to deepen the company's innovation in drug development and enhance its core competitiveness, leveraging Peking University's research strengths and Sunshine Nuohuo's capabilities in drug development and commercialization [12]. - The funding for this partnership will come from the company's own resources, ensuring no adverse impact on cash flow or existing operations [12].

Core Viewpoint - The company, Sunlight Nuohe (688621.SH), has announced a collaboration with Peking University Health Science Center to establish the "Peking University Medicine - Sunlight Nuohe Innovative Drug Joint Laboratory" aimed at enhancing independent innovation capabilities and national core competitiveness [1] Group 1: Collaboration Details - The partnership will focus on cutting-edge fields such as cell therapy and gene therapy [1] - The primary goal is to develop clinical candidate drugs, leveraging the strengths of both parties to promote high-quality development in innovative drug research and development [1]

Core Viewpoint - WuXi AppTec is accelerating the divestiture of non-core assets, focusing on its CRDMO (Contract Research, Development, and Manufacturing Organization) business model to enhance drug discovery, laboratory testing, and production services [5][10]. Summary by Sections Asset Sale - WuXi AppTec completed the sale of two subsidiaries for a total of 2.8 billion RMB, with a tax-adjusted net profit increase of approximately 960 million RMB expected [1][3]. - The subsidiaries, which contributed limited revenue, generated about 1.16 billion RMB in revenue, accounting for 3.5% of WuXi AppTec's total revenue for the same period [4][13]. Strategic Focus - The company aims to concentrate resources on its core CRDMO business, enhancing global capabilities and production capacity [4][10]. - Recent asset sales include the divestiture of various non-core businesses, such as clinical research and drug testing, to focus on high-value segments [6][14]. Financial Performance - WuXi AppTec reported a significant increase in profits, with total profit up 96.20% and net profit attributable to shareholders up 101.92% in the first half of 2025 [7][14]. - The revenue breakdown shows that chemical business revenue reached 16.30 billion RMB, a 33.51% increase, while other segments experienced declines [15][16]. Market Outlook - The global pharmaceutical R&D market is projected to grow from 260.6 billion USD in 2023 to 359.2 billion USD by 2028, with a compound annual growth rate (CAGR) of approximately 6.6% [9][17]. - The demand for integrated outsourcing services is expected to rise, particularly among small to medium-sized pharmaceutical companies lacking in-house capabilities [9][17].